
A meta-analysis on the impact of increased vitamin D levels in chronic kidney disease (CKD) patients reveals mixed results. Out of 12 selected trials, vitamin D and VDRA supplementation did not significantly improve vascular markers like FMD (flow-mediated dilation), PWV (pulse wave velocity), and AIx (augmentation index). However, subgroup analysis showed that 2 μg paricalcitol and cholecalciferol were associated with improved FMD. The findings suggest that regulating vitamin D may not effectively reduce the incidence of cardiovascular disease in CKD patients.
Like
Save
Share